Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin ; New York, Springer-Verlag
    • Subject Terms:
    • Abstract:
      Objective: To describe the clinical features of a cohort of individuals with stiff person syndrome spectrum disorders (SPSD) and identify potential early predictors of future disability.
      Background: There is a need to better understand the full spectrum of clinical and paraclinical features and long-term impact of SPSD.
      Design/methods: Observational study from 1997 to 2022 at Johns Hopkins. Clinical phenotypes included classic SPS, partial SPS (limb or trunk limited), SPS-plus (classic features plus cerebellar/brainstem involvement), and progressive encephalomyelitis with rigidity and myoclonus (PERM). Outcome measures were modified Rankin scale (mRS) and use of assistive device for ambulation. Multivariate logistic regression was used to assess significant predictors of outcomes.
      Results: Cohort included 227 individuals with SPSD with mean follow-up of 10 years; 154 classic, 48 SPS-plus, 16 PERM, and 9 partial. Mean age at symptom onset was 42.9 ± 14.1 years, majority were white (69.2%) and female (75.8%). Median time to diagnosis was 36.2 months (longest for SPS-plus and PERM) and 61.2% were initially misdiagnosed. Most had systemic co-morbidities and required assistive devices for ambulation. Female sex (OR 2.08; CI 1.06-4.11) and initial brainstem/cerebellar involvement (OR 4.41; CI 1.63-14.33) predicted worse outcome by mRS. Older age at symptom onset (OR 1.04; CI 1.01-1.06), female sex (OR 1.99; CI 1.01-4.01), Black race (OR 4.14; CI 1.79-10.63), and initial brainstem/cerebellar involvement (OR 2.44; CI 1.04-7.19) predicted worse outcome by use of assistive device. Early implementation of immunotherapy was associated with better outcomes by either mRS (OR 0.45; CI 0.22-0.92) or use of assistive device (OR 0.79; CI 0.66-0.94).
      Conclusions: We present the expanding phenotypic variability of this rare spectrum of disorders and highlight potential predictors of future disability.
      (© 2023. The Author(s).)
    • References:
      Budhram A, Sechi E, Flanagan EP et al (2021) Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry 92(6):645–654. https://doi.org/10.1136/jnnp-2020-325275. (PMID: 10.1136/jnnp-2020-32527533563803)
      McKeon A, Robinson MT, McEvoy KM et al (2012) Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 69(2):230–238. https://doi.org/10.1001/archneurol.2011.991. (PMID: 10.1001/archneurol.2011.99122332190)
      Dalakas MC (2022) Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies. Neurother J Am Soc Exp Neurother. https://doi.org/10.1007/s13311-022-01188-w. (PMID: 10.1007/s13311-022-01188-w)
      Dalakas MC (2009) Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 11(2):102–110. https://doi.org/10.1007/s11940-009-0013-9. (PMID: 10.1007/s11940-009-0013-919210912)
      Moersch FP, Woltman HW (1956) Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome); report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin 31(15):421–427. (PMID: 13350379)
      Wang Y, Tourkevich R, Bosley J, Gold DR, Newsome SD (2021) Ocular motor and vestibular characteristics of antiglutamic acid decarboxylase-associated neurologic disorders. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc 41(4):e665–e671. https://doi.org/10.1097/WNO.0000000000001084. (PMID: 10.1097/WNO.0000000000001084)
      Tsiortou P, Alexopoulos H, Dalakas MC (2021) GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord 14:17562864211003486. https://doi.org/10.1177/17562864211003486. (PMID: 10.1177/17562864211003486338545628013924)
      Solimena M, Folli F, Denis-Donini S et al (1988) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318(16):1012–1020. https://doi.org/10.1056/NEJM198804213181602. (PMID: 10.1056/NEJM1988042131816023281011)
      Newsome SD, Johnson T (2022) Stiff person syndrome spectrum disorders; more than meets the eye. J Neuroimmunol 369:577915. https://doi.org/10.1016/j.jneuroim.2022.577915. (PMID: 10.1016/j.jneuroim.2022.577915357177359274902)
      Bernardo F, Rebordão L, Rêgo A et al (2020) Stiff person spectrum disorders: an illustrative case series of their phenotypic and antibody diversity. J Neuroimmunol 341:577192. https://doi.org/10.1016/j.jneuroim.2020.577192. (PMID: 10.1016/j.jneuroim.2020.57719232087460)
      Martinez-Hernandez E, Ariño H, McKeon A et al (2016) Clinical and immunologic investigations in patients with stiff-person spectrum disorder. JAMA Neurol 73(6):714–720. https://doi.org/10.1001/jamaneurol.2016.0133. (PMID: 10.1001/jamaneurol.2016.0133270654525020136)
      Madlener M, Strippel C, Thaler FS et al (2023) Glutamic acid decarboxylase antibody-associated neurological syndromes: Clinical and antibody characteristics and therapy response. J Neurol Sci 445:120540. https://doi.org/10.1016/j.jns.2022.120540. (PMID: 10.1016/j.jns.2022.12054036608627)
      Strippel C, Herrera-Rivero M, Wendorff M et al (2022) A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. Brain J Neurol. https://doi.org/10.1093/brain/awac119. (PMID: 10.1093/brain/awac119)
      Dalakas MC, Fujii M, Li M, McElroy B (2000) The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55(10):1531–1535. https://doi.org/10.1212/wnl.55.10.1531. (PMID: 10.1212/wnl.55.10.153111094109)
      Benavides DR, Newsome SD (2016) Serotonin-norepinephrine reuptake inhibitors may exacerbate stiff-person syndrome. Neurol Neuroimmunol Neuroinflamm 3(5):e281. https://doi.org/10.1212/NXI.0000000000000281. (PMID: 10.1212/NXI.0000000000000281276063565004527)
      Ances BM, Dalmau JO, Tsai J, Hasbani MJ, Galetta SL (2005) Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase antibodies. Am J Ophthalmol 140(1):142–144. https://doi.org/10.1016/j.ajo.2004.12.052. (PMID: 10.1016/j.ajo.2004.12.05216038662)
      Saiz A, Blanco Y, Sabater L et al (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain J Neurol 131(Pt 10):2553–2563. https://doi.org/10.1093/brain/awn183. (PMID: 10.1093/brain/awn183)
      Honnorat J, Saiz A, Giometto B et al (2001) Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58(2):225–230. https://doi.org/10.1001/archneur.58.2.225. (PMID: 10.1001/archneur.58.2.22511176960)
      Li Y, Thakore N (2020) An appraisal of electrodiagnostic studies in stiff person syndrome. J Clin Neuromuscul Dis 22(2):84–89. https://doi.org/10.1097/CND.0000000000000302. (PMID: 10.1097/CND.000000000000030233214393)
      Koshorek J, Maldonado DP, Reyes-Mantilla M, Obando D, Wang Y, Newsome S. The evolving spectrum of gastrointestinal dysfunction in stiff person syndrome (4200). Neurology. 2021;96(15 Supplement). https://n.neurology.org/content/96/15_Supplement/4200 . Accessed 24 Oct 2022.
      Chan CK, Pimentel Maldonado DA, Wang Y, Obando D, Hughes AJ, Newsome SD (2022) Cognitive and mood profiles among patients with stiff person syndrome spectrum disorders. Front Neurol 13:865462. https://doi.org/10.3389/fneur.2022.865462. (PMID: 10.3389/fneur.2022.865462356930229184450)
      Lambe J, Rothman A, Prince J, Saidha S, Calabresi PA, Newsome SD (2020) Retinal pathology occurs in stiff-person syndrome. Neurology 94(20):e2126–e2131. https://doi.org/10.1212/WNL.0000000000008943. (PMID: 10.1212/WNL.0000000000008943319246847526674)
      Caffrey D, Finn CT, Song SM, Burton F, Arsan C (2021) Stiff-person syndrome and psychiatric comorbidities: a systematic review. J Acad Consult-Liaison Psychiatry 62(1):3–13. https://doi.org/10.1016/j.psym.2020.08.005. (PMID: 10.1016/j.psym.2020.08.00533183848)
      Nasri A, Gharbi A, Ouali U et al (2022) Psychiatric symptoms in stiff-person syndrome: a systematic review and a report of two cases. J Acad Consult-Liaison Psychiatry. https://doi.org/10.1016/j.jaclp.2022.07.005. (PMID: 10.1016/j.jaclp.2022.07.00535940576)
      Cervantes CE, Lee Lau H, Binazir TA, O’Brien KO, Cross JS (2017) Why it is not always anxiety: a tough diagnosis of stiff person syndrome. Case Rep Neurol Med 2017:7431092. https://doi.org/10.1155/2017/7431092. (PMID: 10.1155/2017/7431092288908375584351)
      Souissi MA, Bellakhal S, Gharbi E, Abdelkefi I, Douggui MH (2020) A stiff person syndrome misdiagnosed as a psychiatric illness: a case report. Curr Rheumatol Rev 16(4):343–345. https://doi.org/10.2174/1573397115666191116101240. (PMID: 10.2174/157339711566619111610124031738138)
      Dalakas MC (2005) The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 252(Suppl 1):I19-25. https://doi.org/10.1007/s00415-005-1105-4. (PMID: 10.1007/s00415-005-1105-415959668)
      Yi J, Dalakas MC (2022) Long-term effectiveness of IVIg maintenance therapy in 36 patients with GAD antibody-positive Stiff-Person syndrome. Neurol Neuroimmunol Neuroinflamm 9(5):e200011. https://doi.org/10.1212/NXI.0000000000200011. (PMID: 10.1212/NXI.0000000000200011357985619262284)
      Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345(26):1870–1876. https://doi.org/10.1056/NEJMoa01167. (PMID: 10.1056/NEJMoa0116711756577)
      Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B (2017) A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol 82(2):271–277. https://doi.org/10.1002/ana.25002. (PMID: 10.1002/ana.25002287495495755707)
      Aljarallah S, Wang Y, Shoemaker T, Newsome S. Long-term Rituximab Use Benefits Patients with Stiff Person Syndrome (P2.2–033). Neurology. 2019;92(15 Supplement). https://n.neurology.org/content/92/15_Supplement/P2.2-033 . Accessed 24 Oct 2022.
      Sriwastava S, Srinivas M, Kanna A, Yarraguntla K, Jowkar A, George E (2019) Anti-glutamic acid decarboxylase antibody (GAD) syndromes may have more aggressive disease course in African Americans and early onset of presentation compare to Caucasians group. eNeurologicalSci. 17:100208. https://doi.org/10.1016/j.ensci.2019.100208. (PMID: 10.1016/j.ensci.2019.100208316462046804399)
      Matsui N, Tanaka K, Ishida M et al (2023) Prevalence, clinical profiles, and prognosis of stiff-person syndrome in a Japanese Nationwide Survey. Neurol Neuroimmunol Neuroinflamm 10(6):e200165. https://doi.org/10.1212/NXI.0000000000200165. (PMID: 10.1212/NXI.00000000002001653773981010519438)
      Bose S, Thompson JP, Sadalage G, Karim A, Jacob S (2021) Quantitative assessment of response to long-term treatment with intravenous immunoglobulin in patients with stiff person syndrome. Mov Disord Clin Pract 8(6):868–874. https://doi.org/10.1002/mdc3.13261. (PMID: 10.1002/mdc3.13261344014048354084)
      Galli JR, Austin SD, Greenlee JE, Clardy SL (2018) Stiff person syndrome with Anti-GAD65 antibodies within the national veterans affairs health administration. Muscle Nerve 58(6):801–804. https://doi.org/10.1002/mus.26338. (PMID: 10.1002/mus.2633830192027)
      Aljarallah S, Newsome SD (2021) Use of subcutaneous immunoglobulin in stiff person syndrome: case series. Medicine (Baltimore) 100(12):e25260. https://doi.org/10.1097/MD.0000000000025260. (PMID: 10.1097/MD.000000000002526033761724)
      Fileccia E, Rinaldi R, Minicuci GM et al (2020) Subcutaneous immunoglobulin for maintenance therapy in stiff-person syndrome: One-year follow-up in two patients. Neuromuscul Disord NMD 30(11):921–924. https://doi.org/10.1016/j.nmd.2020.09.024. (PMID: 10.1016/j.nmd.2020.09.02433060024)
      Sanchez K, Ullah A, Waler AR, Chakfe Y (2019) Improving ambulation and minimizing disability with therapeutic plasma exchange in a stiff-person syndrome patient with recurrent falls. Cureus 11(11):e6209. https://doi.org/10.7759/cureus.6209. (PMID: 10.7759/cureus.6209318904106925374)
      Albahra S, Yates SG, Joseph D, De Simone N, Burner JD, Sarode R (2019) Role of plasma exchange in stiff person syndrome. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 58(3):310–312. https://doi.org/10.1016/j.transci.2019.03.015. (PMID: 10.1016/j.transci.2019.03.015)
      Mercure-Corriveau N, Roy S, Hu C et al (2023) Therapeutic plasma exchange in the management of stiff person syndrome spectrum disorders: a case series and review of the literature. Ther Adv Neurol Disord 16:17562864231180736. https://doi.org/10.1177/17562864231180736. (PMID: 10.1177/175628642311807363752971910387686)
      Rineer S, Fretwell T (2017) Evaluation of treatment outcomes in patients with stiff person syndrome with rituximab vs. standard of care. Cureus 9(6):e1387. https://doi.org/10.7759/cureus.1387. (PMID: 10.7759/cureus.1387287759275524563)
      Burt RK, Balabanov R, Han X et al (2021) Autologous hematopoietic stem cell transplantation for stiff-person spectrum disorder: a clinical trial. Neurology 96(6):e817–e830. https://doi.org/10.1212/WNL.0000000000011338. (PMID: 10.1212/WNL.000000000001133833318163)
      Kass-Iliyya L, Snowden JA, Thorpe A et al (2021) Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. J Neurol 268(1):265–275. https://doi.org/10.1007/s00415-020-10054-8. (PMID: 10.1007/s00415-020-10054-832785838)
      Rakocevic G, Alexopoulos H, Dalakas MC (2019) Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurol. https://doi.org/10.1186/s12883-018-1232-z. (PMID: 10.1186/s12883-018-1232-z306061316317182)
    • Contributed Indexing:
      Keywords: Anti-GAD65; Progressive encephalomyelitis with rigidity and myoclonus; Stiff limb syndrome; Stiff person syndrome
    • Publication Date:
      Date Created: 20231211 Date Completed: 20240328 Latest Revision: 20240517
    • Publication Date:
      20240517
    • Accession Number:
      PMC10973082
    • Accession Number:
      10.1007/s00415-023-12123-0
    • Accession Number:
      38078976